- Home
- DARE vs CLPS Comparison
DARE vs CLPS Comparison
Compare DARE & CLPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DARE
- CLPS
- Stock Information
- Founded
- DARE 2015
- CLPS 2005
- Country
- DARE United States
- CLPS Hong Kong
- Employees
- DARE N/A
- CLPS N/A
- Industry
- DARE Biotechnology: Pharmaceutical Preparations
- CLPS Computer Software: Prepackaged Software
- Sector
- DARE Health Care
- CLPS Technology
- Exchange
- DARE Nasdaq
- CLPS Nasdaq
- Market Cap
- DARE 26.3M
- CLPS 26.0M
- IPO Year
- DARE N/A
- CLPS 2018
- Fundamental
- Price
- DARE $2.40
- CLPS $0.91
- Analyst Decision
- DARE Strong Buy
- CLPS
- Analyst Count
- DARE 3
- CLPS 0
- Target Price
- DARE $12.50
- CLPS N/A
- AVG Volume (30 Days)
- DARE 39.0K
- CLPS 11.9K
- Earning Date
- DARE 08-11-2025
- CLPS 03-05-2025
- Dividend Yield
- DARE N/A
- CLPS 14.23%
- EPS Growth
- DARE N/A
- CLPS N/A
- EPS
- DARE N/A
- CLPS N/A
- Revenue
- DARE $25,909.00
- CLPS $153,816,045.00
- Revenue This Year
- DARE $99,756.91
- CLPS N/A
- Revenue Next Year
- DARE $119.77
- CLPS N/A
- P/E Ratio
- DARE N/A
- CLPS N/A
- Revenue Growth
- DARE N/A
- CLPS 5.81
- 52 Week Low
- DARE $2.35
- CLPS $0.68
- 52 Week High
- DARE $4.60
- CLPS $1.70
- Technical
- Relative Strength Index (RSI)
- DARE 30.40
- CLPS 42.08
- Support Level
- DARE $2.35
- CLPS $0.90
- Resistance Level
- DARE $2.95
- CLPS $0.93
- Average True Range (ATR)
- DARE 0.11
- CLPS 0.05
- MACD
- DARE -0.04
- CLPS -0.00
- Stochastic Oscillator
- DARE 7.04
- CLPS 24.91
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
About CLPS CLPS Incorporation
CLPS Inc is a holding company. The company through its subsidiaries provides information technology consulting and solutions institutions in the banking, insurance, and financial sectors, both in China and globally. Its products are Risk Control Platform, Transaction Acquiring Platform, Debt Collection Platform, Virtual Bank Training Platform, Credit Card System, and other related products. The company generates its revenue from IT consulting services, Customized IT solution services, and others. Generating the majority of its revenue from the IT consulting service.